Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells

Nature Medicine

Volumn 9, Issue 7, 2003, Pages 952-958

  Cui, Yan ^a,c   Kelleher, Erin ^a   Straley, Erin ^a   Fuchs, Ephraim ^a   Gorski, Kevin ^a   Levitsky, Hyam ^a   Borrello, Ivan ^a   Civin, Curt I ^a   Schoenberger, Stephen P ^b   Cheng, Linzhao ^a   Pardoll, Drew M ^a   Whartenby, Katharine A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DENDRITIC CELL; DNA MODIFICATION; FLOW CYTOMETRY; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENE; TUMOR IMMUNITY;

ANIMALS; ANTIGENS; ANTIGENS, CD40; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DENDRITIC CELLS; HEMAGGLUTINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; LENTIVIRUS; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; SPLEEN; SURVIVAL RATE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSPLANTATION, AUTOLOGOUS;

ANIMALIA; LENTIVIRUS;

EID: 0038379169     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm882     Document Type: Article

References (28)

1. Banchereau, J. et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61, 6451-6458 (2001).
2. Nestle, F.O. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328-332 (1998).
3. Thurner, B. et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190, 1669-1678 (1999).
4. Chang, A.E. et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 8, 1021-1032 (2002).
5. Timmerman, J.M. et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99, 1517-1526 (2002).
6. Murphy, G.P. et al. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 39, 54-59 (1999).
7. Nair, S.K. et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg. 235, 540-549 (2002).
8. Kugler, A. et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 6, 332-336 (2000).
9. Fong, L. et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 98, 8809-8814 (2001).
10. Eggert, A.A. et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res. 59, 3340-3345 (1999).
11. Cayeux, S. et al. Direct and indirect T cell priming by dendritic cell vaccines. Eur. J. Immunol. 29, 225-234 (1999).
12. Borrello, I.M. & Sotomayor, E.M. Cancer vaccines for hematologic malignancies. Cancer Control 9, 138-151 (2002).
13. Teshima, T. et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res. 61, 162-171 (2001).
14. Anderson, L.D., Jr., Savary, C.A. & Mullen, C.A. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. Blood 95, 2426-2433 (2000).
15. Asavaroengchai, W., Kotera, Y. & Mule, J.J. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Natl. Acad. Sci. USA 99, 931-936 (2002).
16. Cui, Y. et al. Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. Blood 99, 399-408 (2002).
17. Woods, N.B., Ooka, A. & Karlsson, S. Development of gene therapy for hematopoietic stem cells using lentiviral vectors. Leukemia 16, 563-569 (2002).
18. Lynch, D.H. Induction of dendritic cells (DC) by Flt3 Ligand (FL) promotes the generation of tumor-specific immune responses in vivo. Crit. Rev. Immunol. 18, 99-107 (1998).
19. Diehl, L. et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5, 774-779 (1999).
20. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5, 780-787 (1999).
21. Staveley-O'Carroll, K. et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95, 1178-1183 (1998).
22. Mackall, C.L. et al. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J. Immunol. 156, 4609-4616 (1996).
23. Borrello, I. et al. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 95, 3011-3019 (2000).
24. Merad, M., Sugie, T., Engleman, E.G. & Fong, L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 99, 1676-1682 (2002).
25. Borges, L. et al. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. J. Immunol. 163, 1289-1297 (1999).
26. Dhodapkar, M.V., Steinman, R.M., Krasovsky, J., Munz, C. & Bhardwaj, N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193, 233-238 (2001).
27. Whartenby, K.A. et al. Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. Blood 100, 3147-3154 (2002).
28. Matzinger, P. The JAM test. A simple assay for DNA fragmentation and cell death. J. Immunol. Meth. 145, 185-192 (1991).